Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile SpasmsDENVER and SINGAPORE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced that they had received authorization from the US Food and Drug Administration for an Investigational New Drug (IND) application for CER-0001 in IS, also referred to as West Syndrome. CER-0001 is an investigational, oral drug designed to induce a state of ketosis and address the metabolic deficit in the brains of children with IS, a rare and serious form of childhood epilepsy.
Cerecin Announces Abstract on New Infantile Spasms Data Accepted for Oral Presentation at the International League Against Epilepsy EME Congress 2022SINGAPORE and DENVER, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced that a poster showcasing new data on investigational CER-0001 (tricaprilin) in Infantile Spasms (also known as West Syndrome) has been accepted for virtual oral presentation at the hybrid International League Against Epilepsy EME Congress, held in Riyadh from November 16-19, 2022. The data will be presented by Cerecin’s Chief Medical Officer, Dr. Marc Cantillon.
Results of Pilot Study of CER-0001 in Migraine support advancement into a pivotal global Phase 2/3 studySINGAPORE and DENVER, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced that data from RELIEF1, a double-blind, randomized, placebo-controlled study investigating the safety and efficacy of twice daily administration of CER-0001 for the prevention of migraine, found an efficacy signal that warrants further development in a pivotal Phase 2/3 study.
Cerecin appoints Dr. Marc Cantillon as Chief Medical OfficerSINGAPORE and DENVER, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced the appointment of Marc Cantillon, MD, as Chief Medical Officer (CMO) of the Company.
Cerecin closes Series IIB financing to advance CER-0001 clinical programs and build pipeline in neuro-metabolism drug developmentSeries IIB Financing was supported by existing and new investors in South Korea.Proceeds strengthen Cerecin’s operating position to advance the clinical studies of CER-0001 in migraine and infantile spasms.New funds will also be used to build Cerecin’s pipeline and advance plans for a pivotal trial in Alzheimer’s disease.
